Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 4/2021

LEVOFLOXACIN VERSUS CEFIXIME AS AN EMPIRIC TREATMENT IN ACUTE BACTERIAL PROSTATITIS

CĂTĂLIN PRICOP 1,2#, DRAGOȘ PUIA 1,2, DANIEL ANDONE 2, SILVIU LAȚCU 3, GEORGE DANIEL RĂDĂVOI 5*, IOAN CORDOȘ 5#, VIOREL JINGA 5, TUDOR PROCA 5, ALIN CUMPĂNAȘ 3

1“Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Medicine, Discipline of Urology, 16 Universităţii Street, 700115, Iaşi, Romania
2“Dr. C.I. Parhon” Clinical Hospital, Clinic of Urology, 50 Carol I Boulevard, 700503, Iaşi, Romania
3“Victor Babeș” University of Medicine and Pharmacy, Faculty of Medicine, Discipline of Urology, Timișoara, Romania
4“Grigore T. Popa” University of Medicine and Pharmacy, Faculty of Medicine, Department of Mother and Child Medicine, 16 Universităţii Street, Iaşi, Romania
5“Carol Davila” University of Medicine and Pharmacy, Faculty of Medicine, Discipline of Urology, 37 Dionisie Lupu Street, Bucharest, Romania

Download Full Article PDF

Acute bacterial prostatitis (ABP) is a clinical condition frequently encountered in clinical practice, but there is a lack of consensus for the diagnosis, investigations, and treatment for this pathology. We have enrolled patients diagnosed with acute prostatitis in three academic urological centres between 2019 - 2020 and followed-up prospectively their evolution under two different frequently used antibiotics-fluoroquinolones and cephalosporins, both combined or not with alpha-blockers. All patients received standard start-up treatment. A total of 154 patients were included. Both groups had similar side effects rates ranging from 8.97% to 11.84%. Both groups had similar positive urine culture 15.38% for group A, respectively 14.47% for group B. Although it is an ongoing study, we can confirm that fluoroquinolones and cephalosporins, with or without alpha-blocker, are as effective and tolerated in enhancing empirical treatment initiated at admission for patients with acute bacterial prostatitis.